7.92 0.00 (0.00%)
After hours: 5:07PM EDT
|Bid||7.91 x 3000|
|Ask||7.92 x 800|
|Day's Range||7.77 - 8.08|
|52 Week Range||2.23 - 12.22|
|Beta (3Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.69|
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on Tuesday, September 24, 2019 at The Parker New York Hotel in New York City.
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston, MA. In addition, Dr. Marc Schegerin will participate in the hosted panel discussion: Focusing the Laser on Precision Oncology, at 3:00 PM. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule (ARQL) delivered earnings and revenue surprises of 11.11% and -80.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On Wednesday, August 7, Arqule (NASDAQ: ARQL ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Wall Street expects an EPS loss of 9 cents ...
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
ArQule, Inc. today announced that Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 at The St.
ArQule (ARQL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 10,637,500 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $103.7 million. SVB Leerink and RBC Capital Markets acted as joint bookrunning managers for the offering.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $90.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.
ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by ArQule.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
ArQule, Inc. (ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.m. ET at the The Mandarin Oriental New York, New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.